Sight Sciences is a cash-burning, high-beta medical device name that has traded 8.0% above its analyst target, with a 3-of-4 earnings beat streak but weak quality and insider selling.
Thesis pillars
- Price Above Analyst Target→Stable
- Quality Below Floor→Stable
- Earnings Beat Streak→Stable
- +2 more pillars — see the Why tab for full reasoning
Pillars as of Oct 11, 2026, based on the 10-K filed Mar 4, 2026
Sight Sciences, Inc. (SGHT) Stock Analysis
Healthcare · Medical Devices
Sell if holding. Engine safety override at $9.76: Quality below floor (3.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10. Specifically: Below-average business quality.
Sight Sciences develops interventional ophthalmic technologies across two segments: Interventional Glaucoma (OMNI and SION for MIGS procedures) and Interventional Dry Eye (TearCare for meibomian gland disease). The company estimates addressable U.S. markets of about $6.0 billion... Read more
Sell if holding. Engine safety override at $9.76: Quality below floor (3.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10. Specifically: Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Score 5.2/10, moderate confidence.
Passes 6/8 gates (positive momentum, clean insider activity, news boost analyst 0.60, earnings proximity 117d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: aggressive.
About Sight Sciences, Inc.
About Sight Sciences, Inc.
Sight Sciences sells three FDA-cleared interventional ophthalmology devices — OMNI and SION for microinvasive glaucoma surgery, and TearCare for meibomian gland disease — with OMNI expected to remain the majority of revenue over the next twelve months. The company operates direct commercial teams in the United States, United Kingdom, and Germany, selling into other European markets through distributors. Sight Sciences reported a $38.4 million net loss in 2025 against a $384.7 million accumulated deficit.
Sight Sciences generates revenue from OMNI and SION sales to ophthalmic surgeons, ambulatory surgery centers, and hospital outpatient departments performing MIGS procedures, billed to Medicare, Medicaid, and commercial payors under Category I CPT codes 66174 (canaloplasty) and 65820 (goniotomy), while TearCare is billed under the newer Category III CPT code 0563T, for which reimbursement remains uneven across Medicare Administrative Contractors and commercial plans. The company's more than 100-person commercial team focuses on physician training and clinical education to drive adoption, supported by a growing base of peer-reviewed publications — 34 articles on OMNI since 2018 alone. Manufacturing is outsourced to third-party manufacturers rather than produced in-house. Looking forward, Sight Sciences is running early-stage trials for a next-generation Helix Surgical System and an OMNI 3.0 device, both first-in-human studies registered in 2025.
Show full overview
Payer policy has already moved OMNI's economics in a measurable way: CMS cut the Medicare Physician Fee Schedule payment tied to CPT code 66174 (the canaloplasty code most OMNI procedures bill under) from approximately $950 in 2021 to $545 in 2026, a decline the company says has made the code less attractive to providers. Separately, in 2023 five of seven Medicare Administrative Contractors proposed local coverage determinations classifying OMNI's canaloplasty-trabeculotomy procedure as investigational; though withdrawn, the replacement policies still bar coverage when a MIGS procedure combines with an aqueous shunt or stent, a restriction the company says has already reduced MIGS claims volumes.
See also: Healthcare · Medical Devices
From Sight Sciences, Inc.'s most recent 10-K filing, extracted August 23, 2026.
Recent developments
updated Nov 5, 2026Recent Developments — Sight Sciences, Inc.
Latest news
- NEWS Sight Sciences Announces Plans to Present at Upcoming Healthcare Conferences — fiscal.ai Nov 5, 2026 neutral
- NEWS Piper Sandler Maintains Overweight Rating and Raises Price Target for Sight Sciences — fiscal.ai Nov 5, 2026 positive
- NEWS Piper Sandler Reiterates Overweight on Sight Sciences, Raises Price Target to $12 — benzinga Nov 5, 2026 positive
- NEWS CMS Establishes New Direct Practice Expense Supply Code for TearCare System — fiscal.ai Nov 5, 2026 neutral
- NEWS Sight Sciences Says Centers For Medicare & Medicaid Services Establishes New Direct Practice Expense Supply Code For Sin — benzinga Nov 5, 2026 positive
Latest item Nov 5, 2026 · Generated 2026-11-06T11:58:11Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- MEDIUMProductOMNI10-K Item 1A: 'We believe that OMNI sales will continue to account for the majority of our revenue over the next twelve months.'
Material Events(8-K, last 90d)
- 2026-08-10Item 5.02LOWSight Sciences appointed Kashif Rashid (ex-Nevro Corp GC) as Chief Legal Officer and Corporate Secretary, effective August 10, 2026.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Unprofitable operations — net margin -35.7%. Quality floor flags this regardless of sector context.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $9.76: Quality below floor (3.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10. Specifically: Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $9.08. Score 5.2/10, moderate confidence.
Analyst target $8.85 reached (−9.4% from $9.76); no take-profit level is published. Prior stop was $9.08. Stop-loss: $9.08.
Target reached (-9.4% upside); Quality below floor (3.4 < 4.0).
Sight Sciences, Inc. trades at a P/E of N/A (forward -24.4). TrendMatrix value score: 4.8/10. Verdict: Sell.
14 analysts rate SGHT, with a consensus score of 4.1/5. 6 analysts publish price targets averaging $10.
What does Sight Sciences, Inc. do?Sight Sciences develops interventional ophthalmic technologies across two segments: Interventional Glaucoma (OMNI and...
Sight Sciences develops interventional ophthalmic technologies across two segments: Interventional Glaucoma (OMNI and SION for MIGS procedures) and Interventional Dry Eye (TearCare for meibomian gland disease). The company estimates addressable U.S. markets of about $6.0 billion for glaucoma and $2.4 billion for dry eye, selling mainly through a direct U.S. sales team, with OMNI expected to remain the majority of near-term revenue.